1. Introduction {#sec1}
===============

Cirrhosis is the end stage of chronic liver disease, which is histologically characterized by fibrosis, scar, and regenerative nodules leading to structural deformation \[[@B1]\]. A major consequence of advanced cirrhosis is portal hypertension, which leads to the development of gastroesophageal varices (GEVs) \[[@B2]\]. Endoscopy should be performed at the time of first diagnosis of liver cirrhosis \[[@B3]\]. GEVs are observed in about 50% of patients with cirrhosis, and 8% of patients without GEVs develop them each year. Patients with no or small varices and without prior history of variceal bleeding should undergo endoscopic surveillance every 1-2 years. Bleeding from GEVs results in a mortality of 5-20% at 6 weeks. Endoscopic treatment, such as endoscopic variceal ligation (EVL) or tissue adhesive injection, is recommended for the management of high-risk varices and acute variceal bleeding \[[@B3]--[@B5]\]. However, patients undergoing endoscopic treatment for variceal bleeding have a high variceal recurrence rate of 8-48% \[[@B6], [@B7]\], a rebleeding rate of 20-43%, and a bleeding related mortality of 19-34% \[[@B8]\]. Therefore, after endoscopic treatment, repeated EVL should be performed every 1-2 weeks until variceal obliteration. The first endoscopic surveillance for variceal recurrence should be performed within 1-3 months after variceal obliteration, and then endoscopic surveillance should be repeated every 6-12 months \[[@B5]\].

Despite endoscopy is the golden approach for diagnosis and surveillance of GEVs according to the current practice guideline and consensus, it is often limited by increased invasiveness, patients\' discomfort and poor adherence, and high cost \[[@B9]--[@B11]\]. Recently, noninvasive blood tests have been used to diagnose GEVs \[[@B12], [@B13]\], such as aspartate aminotransferase (AST) to platelet (PLT) ratio index (APRI), AST to alanine aminotransferase (ALT) ratio (AAR), fibrosis 4 index (FIB-4), Lok score, and King score. Contrast-enhanced computed tomography (CT), a conventional diagnostic imaging tool in patients with liver diseases, has also been explored for the assessment of GEVs \[[@B14]--[@B17]\]. Additionally, a combination of blood tests with imaging examination for screening GEVs, such as PLT count to spleen diameter ratio (PSR), has been frequently explored \[[@B18]\].

Notably, the performance of these diagnostic alternatives may be heterogeneous among different study populations. However, until now, no study has evaluated their diagnostic accuracy according to the patient characteristics \[[@B11]\]. For this reason, we conducted a retrospective observational study to evaluate the accuracy of blood tests, PSR, and contrast-enhanced CT for diagnosing esophageal varices (EVs) and gastric varices (GVs) in cirrhotic patients with and without variceal bleeding or previous endoscopic variceal therapy.

2. Methods {#sec2}
==========

2.1. Patients {#sec2.1}
-------------

This was a single-center retrospective observational study on the basis of our prospective database regarding cirrhotic patients undergoing both contrast-enhanced CT and upper gastrointestinal endoscopy. This study was approved by the medical ethical committee of our hospital and the approval number was \[k (2018) 08\]. The patients\' informed consents were waived. All patients consecutively admitted to our department from December 2014 to October 2018 were potentially eligible.

The inclusion criteria were as follows: (1) patients had a diagnosis of liver cirrhosis according to the medical history, clinical features, imaging, and/or histological results and (2) both contrast-enhanced CT and endoscopic examinations were performed at their admissions, and the time interval between the two examinations was within one month. Repeated admission was not excluded.

The exclusion criteria were as follows: (1) patients had a definite diagnosis of malignant tumors, (2) contrast-enhanced CT was performed after endoscopic treatment at their admissions, and (3) contrast-enhanced CT images were not well preserved.

2.2. Groups {#sec2.2}
-----------

According to the previous history of endoscopic treatment for variceal bleeding, history of gastrointestinal bleeding (GIB), and presence of acute upper gastrointestinal bleeding (AUGIB), the patients were divided into four groups: *Primary prophylaxis population* (no history of endoscopic treatment, no history of GIB, and absence of AUGIB)*Acute bleeding population* (no history of endoscopic treatment, but with presence of AUGIB, regardless of history of GIB)*Previous bleeding population* (no history of endoscopic treatment, absence of AUGIB, but with a history of GIB)*Secondary prophylaxis population* (a history of endoscopic treatment for variceal bleeding, but absence of GIB)

As for the *secondary prophylaxis population*, the patients would be further excluded, if the time interval between prior endoscopic treatment and present admission was less than one month \[[@B19]\]. This is primarily because the esophagus and stomach lumen mucosa may not be fully recovered during a short postoperative period, which will cause a potential radiological artifact on CT images and influence its diagnostic performance.

2.3. Data Collection {#sec2.3}
--------------------

The data were collected as follows: age, sex, etiology of liver diseases, ascites, interval between prior endoscopic treatment and present admission, red blood cell (RBC), hemoglobin (Hb), white blood cell (WBC), PLT, total bilirubin (TBIL), direct bilirubin (DBIL), albumin (ALB), ALT, AST, alkaline phosphatase (AKP), *γ*-glutamine transferase (GGT), blood urea nitrogen (BUN), serum creatinine (SCr), prothrombin time (PT), activated partial thromboplastin time (APTT), and international normalized ratio (INR). The maximum diameter of the spleen was measured on axial contrast-enhanced CT images. The Child-Pugh \[[@B20]\] model for end-stage of liver disease (MELD) \[[@B21]\], APRI \[[@B22]\], AAR \[[@B23]\], FIB-4 \[[@B24]\], Lok \[[@B25]\], King \[[@B26]\], and PSR \[[@B27]\] scores were calculated as follows: $$\begin{matrix}
{\text{Child} - \text{Pugh score} = \text{ALB score} + \text{TBIL score} + \text{INR score} + \text{ascites score} + \text{hepatic encephalopathy score},} \\
{\text{MELD score} = 9.57 \times \ln\left\lbrack {\text{Cr }\left( {\mu\text{mol}/\text{L}} \right) \times 0.011} \right\rbrack + 3.78 \times \ln\left\lbrack {\text{TBIL }\left( {\mu\text{mol}/\text{L}} \right) \times 0.058} \right\rbrack + 11.2 \times \ln\left( \text{INR} \right) + 6.43,} \\
{\text{APRI} = \frac{\left( {\text{AST}/\text{upper limit of normal}} \right) \times 100}{\text{PLT}},} \\
{\text{AAR} = \frac{\text{AST}}{\text{ALT}},} \\
{\text{FIB}‐4 = \frac{\text{age} \times \text{AST}}{\text{PLT} \times \text{AL}\text{T}^{({1/2})}},} \\
{\text{King} = \frac{\text{age} \times \text{AST} \times \text{INR}}{\text{PLT}},} \\
{\text{logodds} = - 5.56 - 0.0089 \times \text{PLT} + 1.26 \times \left( \frac{\text{AST}}{\text{ALT ratio}} \right) + 5.27 \times \text{INR},} \\
{\text{Lok} = \frac{\exp\,\left( \text{logodds} \right)}{1 + \exp\,\left( \text{logodds} \right)},} \\
{\text{PSR} = \frac{\text{PLT}}{\text{spleen diameter}}.} \\
\end{matrix}$$

2.4. Contrast-Enhanced CT Images {#sec2.4}
--------------------------------

Two observers (QL and RW) used the patients\' names or case numbers to search contrast-enhanced CT images in the PowerRIS system. Notably, they were blinded to the laboratory and endoscopic findings when the CT images were retrospectively analyzed. They independently evaluated the presence of GEVs. EVs or GVs were defined as enhancing lesions abutted the luminal surface of the esophageal or gastric wall or protruded into esophageal or gastric luminal space at the portal vein phases of contrast-enhanced CT images \[[@B28], [@B29]\]. They also independently selected the CT layer with the maximum diameter of varices. In cases of any inconsistency in measuring the maximum diameter of varices between the two observers, a discussion with another investigator (XQ) was made until a consensus was achieved. Additionally, they evaluated the spleen and measured the maximum diameter of the spleen on contrast-enhanced CT images.

2.5. Endoscopy {#sec2.5}
--------------

In the present study, an endoscopist (DS) underwent all endoscopic examinations. The shape of EVs and red color (RC) signs were described, and then the grade of EVs was evaluated. The grade of EVs is classified into no, mild, moderate, and severe according to the 2008 Hangzhou consensus \[[@B30]\]. The detailed definitions are as follows: (1) mild EVs: straight or slight tortuous EVs without RC signs; (2) moderate EVs: straight or slightly tortuous EVs with RC signs or serpentine tortuous uplifted EVs without RC signs; and (3) severe EVs: serpentine tortuous uplifted EVs with RC signs or beaded, nodular, or tumor-like EVs with or without RC signs. EVs needing treatment (EVNTs) were further defined as moderate and severe EVs. The presence of GVs was also evaluated. GVs needing treatment (GVNTs) were further defined as large GVs or RC signs in the GVs at the discretion of our endoscopist.

2.6. Statistical Analysis {#sec2.6}
-------------------------

All statistical analyses were performed using the SPSS software version 20.0 (IBM Corp, Armonk, NY, USA) and MedCalc software version 11.4.2.0 (MedCalc Software, Mariakerke, Belgium). Data were expressed as mean ± standard deviation, median and range, or frequencies and percentages. Kappa statistics were used to explore the agreement of diagnosing presence of EVs and GVs between two observers. Receiver operating characteristic (ROC) curve was used to explore the diagnostic performance of blood tests, PSR, and contrast-enhanced CT. We calculated the area under the curve (AUC) and compared them by using the DeLong test. *P* \< 0.05 was considered statistically significant. Additionally, we determined the optimal cutoff values of contrast-enhanced CT by reaching the maximal negative predictive value (NPV) and then calculated the rates of spared endoscopy and missed varices. The bar charts were drawn by the Excel version 16.0 (Microsoft Corp, Redmond, Washington, USA).

3. Results {#sec3}
==========

3.1. Patients {#sec3.1}
-------------

A total of 430 cirrhotic patients underwent both contrast-enhanced CT and endoscopic examinations. Finally, a total of 279 cirrhotic patients were included ([Figure 1](#fig1){ref-type="fig"}). Baseline characteristics are shown in [Table 1](#tab1){ref-type="table"}. Results of kappa statistics were shown in Supplementary [](#supplementary-material-1){ref-type="supplementary-material"}.

3.2. Primary Prophylaxis Population {#sec3.2}
-----------------------------------

Seventy patients were included in this group. Prevalence of EVs, EVNTs, GVs, and GVNTs was 61.4% (43/70), 37.1% (26/70), 25.7% (18/70), and 11.4% (8/70), respectively. As for EVs, only contrast-enhanced CT, Lok score, and PSR had statistically significant diagnostic performance; as for EVNTs, only contrast-enhanced CT and PSR had statistically significant diagnostic performance; as for GVs, only contrast-enhanced CT, AAR score, Lok score, and PSR had statistically significant diagnostic performance; as for GVNTs, only contrast-enhanced CT had statistically significant diagnostic performance ([Table 2](#tab2){ref-type="table"}).

The presence of EVs and diameter of EVs could be evaluated on CT in all of the 70 patients. The diameter of EVs measured on contrast-enhanced CT \< 0.50 cm should be considered as the optimal cutoff value for ruling out the EVNTs. By using this cutoff value, 47.8% (32/67) of endoscopies were spared, and no (0/32) EVNTs was missed ([Figure 2(a)](#fig2){ref-type="fig"}).

After a discussion among investigators, the presence of GVs could not be evaluated on CT in one patient and the diameter of GVs could not be measured on CT in 3 patients. The diameter of GVs measured on contrast-enhanced CT \< 1.09 cm should be considered as the optimal cutoff value for ruling out the GVNTs. By using this cutoff value, 76.6% (49/64) of endoscopies were spared, but 4.1% (2/49) of GVNTs were missed ([Figure 2(a)](#fig2){ref-type="fig"}).

3.3. Acute Bleeding Population {#sec3.3}
------------------------------

Thirty-eight patients were included in this group. Prevalence of EVs, EVNTs, GVs, and GVNTs was 92.1% (35/38), 71.1% (27/38), 50.0% (19/38), and 39.5% (15/38), respectively. As for EVs, contrast-enhanced CT, APRI score, FIB-4 score, King score, Lok score, and PSR had statistically significant diagnostic performance; as for EVNTs, only contrast-enhanced CT and PSR had statistically significant diagnostic performance; as for GVs and GVNTs, all alternatives did not have any statistically significant diagnostic performance ([Table 2](#tab2){ref-type="table"}).

The presence of EVs and diameter of EVs could be evaluated on CT in all of the 38 patients. The diameter of EVs measured on contrast-enhanced CT \< 0.38 cm should be considered as the optimal cutoff value for ruling out the EVNTs. By using this cutoff value, 10.5% (4/38) of endoscopies were spared, and no (0/4) EVNTs was missed ([Figure 2(b)](#fig2){ref-type="fig"}).

After a discussion among investigators, the diameter of GVs could not be measured on CT in 3 patients. The diameter of GVs measured on contrast-enhanced CT \< 1.01 cm should be considered as the optimal cutoff value for ruling out the GVNTs. By using this cutoff value, 45.7% (16/35) of endoscopies were spared, but 25% (4/16) of GVNTs were missed ([Figure 2(b)](#fig2){ref-type="fig"}).

3.4. Previous Bleeding Population {#sec3.4}
---------------------------------

Sixty-seven patients were included in this group. Prevalence of EVs, EVNTs, GVs, and GVNTs was 91.0% (61/67), 73.1% (49/67), 73.1% (49/67), and 53.7% (36/67), respectively. As for EVs, only contrast-enhanced CT had statistically significant diagnostic performance; as for EVNTs, only contrast-enhanced CT and PSR had statistically significant diagnostic performance; as for GVs, only contrast-enhanced CT had statistically significant diagnostic performance; as for GVNTs, only AAR score had statistically significant diagnostic performance ([Table 2](#tab2){ref-type="table"}).

The presence of EVs and diameter of EVs could be evaluated on CT in all of the 67 patients. The diameter of EVs measured on contrast-enhanced CT \< 0.46 cm should be considered as the optimal cutoff value for ruling out the EVNTs. By using this cutoff value, 12.1% (8/66) of endoscopies were spared, and no (0/8) EVNTs was missed ([Figure 2(c)](#fig2){ref-type="fig"}).

After a discussion among investigators, the diameter of GVs could not be measured on CT in 3 patients (3/67). The diameter of GVs measured on contrast-enhanced CT \< 0.95 cm should be considered as the optimal cutoff value for ruling out the GVNTs. By using this cutoff value, 21.9% (14/64) of endoscopies were spared, but 45.5% (5/14) of GVNTs were missed ([Figure 2(c)](#fig2){ref-type="fig"}).

3.5. Secondary Prophylaxis Population {#sec3.5}
-------------------------------------

One hundred and four patients were included in this group. Prevalence of EVs, EVNTs, GVs, and GVNTs was 90.4% (94/104), 40.4% (42/104), 34.6% (36/104), and 15.4% (16/104), respectively.

As for EVs, only contrast-enhanced CT had statistically significant diagnostic performance; as for EVNTs, only contrast-enhanced CT and AAR score had statistically significant diagnostic performance; as for GVs, only contrast-enhanced CT had statistically significant diagnostic performance; as for GVNTs, only contrast-enhanced CT and FIB-4 score had statistically significant diagnostic performance ([Table 2](#tab2){ref-type="table"}).

After a discussion among investigators, the diameter of EVs could not be measured on CT in one patient. The diameter of EVs measured on contrast-enhanced CT \< 0.33 cm should be considered as the optimal cutoff value for ruling out the EVNTs. By using this cutoff value, 7.8% (8/103) of endoscopies were spared, and no (0/8) EVNTs was missed ([Figure 2(d)](#fig2){ref-type="fig"}).

After a discussion among investigators, the presence of GVs could not be evaluated on CT in 2 patients and the diameter of GVs could not be measured on CT in 2 patients. The diameter of GVs measured on contrast-enhanced CT \< 1.11 cm should be considered as the optimal cutoff value for ruling out the GVNTs. By using this cutoff value, 56% (56/100) of endoscopies were spared, but 5.4% (3/56) of GVNTs were missed ([Figure 2(d)](#fig2){ref-type="fig"}).

4. Discussion {#sec4}
=============

Currently, noninvasive diagnosis of GEVs is a hot topic. Severity of liver fibrosis is often in parallel with that of portal hypertension in compensated cirrhosis. Thus, the markers reflecting the severity of liver fibrosis are frequently used for noninvasive assessment of portal hypertension in such patients \[[@B10], [@B31]\]. Considering that liver stiffness measured by transient elastography can stage liver fibrosis and PLT indicates portal hypertension, Baveno VI consensus has recommended that liver stiffness \< 20 kPa combined with PLT \> 150 × 10^9^/L should be a criterion for sparing endoscopy in compensated cirrhosis \[[@B4]\], and only a minority of patients within this Baveno VI criterion have a risk of variceal bleeding \[[@B32]\]. Researchers attempted to further improve its diagnostic accuracy by means of optimizing the thresholds of liver stiffness and PLT or establishing stepwise ruling-out and/or ruling-in strategies (Supplementary [](#supplementary-material-1){ref-type="supplementary-material"}). Noninvasive approaches on the basis of Baveno VI criterion can accurately diagnose EVNTs with a missing rate of \<5% \[[@B33]--[@B43]\]. Despite so, it should be noted that Baveno VI criterion should be appropriate for only patients with compensated cirrhosis without any history of gastrointestinal bleeding or endoscopic treatment. By comparison, few well-established tools have been employed for patients with advanced and decompensated cirrhosis, in whom extrahepatic factors, such as development of extrahepatic collaterals and splanchnic vasodilation, became more important for the progression of portal hypertension than intrahepatic resistance caused by liver fibrosis \[[@B44]\]. In this setting, we have for the first time evaluated the diagnostic accuracy of blood tests, PSR, and contrast-enhanced CT for GEVs according to the severity of liver cirrhosis and portal hypertension, including patients without variceal bleeding (*primary prophylaxis population*), with variceal bleeding (*acute bleeding population* and *previous bleeding population*), and with history of endoscopic treatment for variceal bleeding (*secondary prophylaxis population*).

Our previous meta-analysis demonstrated that APRI, AAR, FIB-4, and Lok scores had low to moderate diagnostic accuracy in predicting the presence of EVs and EVNTs in liver cirrhosis, and their AUCs were 0.6774-0.7885 and 0.7095-0.7448, respectively \[[@B12]\]. Notably, among the studies included in the meta-analysis, most of patients had well-preserved liver function. By comparison, our previous observational study where a majority of patients were decompensated demonstrated that APRI, AAR, FIB-4, and Lok scores had low accuracy for EVs and EVNTs with AUCs of 0.539-0.567 and 0.506-0.544, respectively \[[@B13]\]. Similarly, our present observational study also confirmed that these blood tests were insufficient to replace endoscopy in diagnosing EVs, EVNTs, GVs, and GVNTs in advanced decompensated patients.

PSR had relatively high diagnostic accuracy in predicting the presence of EVs in compensated cirrhotic patients and its AUC was 0.85 \[[@B18]\]. The advantages of PSR as a potential diagnostic alternative for EVs can be explained by the fact that splenomegaly and hypersplenism are common clinical manifestations of portal hypertension, and the PSR model associates decreased PLT with splenomegaly \[[@B27], [@B45]\]. By contrast, our present study suggested that PSR was unsatisfactory for prediction of GEVs. This might be related to the characteristics of our patients that a majority of patients in *primary prophylaxis population* group had Child-Pugh class B or C and all patients in 3 other groups (i.e., *secondary prophylaxis population*, *acute bleeding population*, and *previous bleeding population*) were decompensated with recent or previous bleeding. This was in consistency with the results of a previous study which also included patients receiving secondary prophylaxis and achieved only an AUC of 0.715 \[[@B46]\].

Our previous meta-analysis demonstrated that contrast-enhanced CT had high diagnostic accuracy in predicting the presence of EVs, EVNTs, and GVs, and their AUCs were 0.8958, 0.9461, and 0.9127, respectively \[[@B14]\]. Similarly, another meta-analysis also confirmed that the AUCs were 0.86 and 0.95 in predicting the presence of EVs and GVs, respectively \[[@B15]\]. By comparison, our present study confirmed such high diagnostic accuracy of contrast-enhanced CT in predicting EVs and EVNTs and further suggested that no EVNTs would be missed according to the optimal cutoff value. However, the diagnostic performance of contrast-enhanced CT was insufficient in *secondary prophylaxis population*.

Several pitfalls of contrast-enhanced CT scans for assessment of GEVs should be recognized. First, esophageal wall may form scars and stiffen after repeated endoscopic treatments, in which enhanced vascular shadows do not obviously protrude into esophageal lumen on contrast-enhanced CT images ([Figure 3(a)](#fig3){ref-type="fig"}). Second, during the endoscopic examinations, small EVs may be flattened after dilating esophageal lumen, thereby leading to a missed diagnosis ([Figure 3(b)](#fig3){ref-type="fig"}). Third, the images obtained at the portal vein phases of contrast-enhanced CT scans are inappropriately selected by radiological technicians, in which esophageal venous vessels cannot be obviously enhanced. Fourth, abdominal CT scans are selected for our present study, in which the lesions at middle and upper esophagus cannot be observed. Fifth, contrast-enhanced CT scans can detect GVs located deeply in gastric mucosa \[[@B29]\], which are hard to be distinguished from gastric mucosal folds by endoscopy. Sixth, when the gastric cavity is not fully expanded, small GVs do not protrude from the surface and cannot be differentiated from the gastric mucosa folds on CT images ([Figure 3(c)](#fig3){ref-type="fig"}). Seventh, some GVs appear as irregular vascular shadows on contrast-enhanced CT images, thereby misjudging the maximum diameter of varices ([Figure 3(d)](#fig3){ref-type="fig"}).

Several other advantages of contrast-enhanced CT scans should not be ignored, because it can simultaneously evaluate the severity of liver cirrhosis and its related complications, such as grade or quantification of ascites \[[@B47]\], thrombosis within portal vein system \[[@B48]\], portosystemic collaterals \[[@B49]\], and liver cancer \[[@B50]\], except for GEVs. On the other hand, the disadvantages of contrast-enhanced CT scans include the following. First, the risk of radiation will be increased. Second, contrast-enhanced CT is not applicable to patients with renal failure, hyperthyroidism, and hypersensitivity to contrast media. Third, RC sign is valuable for evaluating the severity of GEVs, but it cannot be observed on contrast-enhanced CT images.

Our study had several limitations. First, Western studies evaluated EVNTs by the size of EVs under endoscopy, and our study employed the Chinese guideline to identify EVNTs. Second, our patients were more severe and had a high prevalence of EVNTs. Because the prevalence of EVNTs should be inversely associated with the rate of spared endoscopy, the rate of sparing more endoscopy was relatively lower in our study ([Figure 4](#fig4){ref-type="fig"}). Third, the present study was of the retrospective nature and performed at a single center. Fourth, the sample size was small in different study population, especially in *acute bleeding population*.

In conclusion, contrast-enhanced CT seemed to have higher diagnostic accuracy for EVs and EVNTs in cirrhotic patients as compared to APRI, AAR, FIB-4, FI, Lok, and King scores and PSR. Among the *secondary prophylaxis population* requiring repeated endoscopic surveillance, contrast-enhanced CT seemed to be the only useful diagnostic alternative for GEVs in cirrhotic patients. However, the potential pitfalls of contrast-enhanced CT, such as stiff and scarred esophagus, small or irregular vascular shadows, and technical errors, can decrease its diagnostic accuracy in *secondary prophylaxis population*.
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Supplementary Table 1: kappa statistics of diagnosing the presence of esophageal varices and gastric varices on contrast-enhanced CT. Supplementary Table 2: diagnostic performance of noninvasive approaches on the basis of Baveno VI criteria: an overview.
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![Flow chart of patient enrollment. CT: computed tomography; AUGIB: acute upper gastrointestinal bleeding.](GRP2019-6704673.001){#fig1}

![Bar charts showing the rates of spared endoscopy and missed varices by contrast-enhanced CT for predicting the presence of EVNTs and GVNTs in different population. (a) Performance in *primary prophylaxis population*. (b) Performance in *acute bleeding population*. (c) Performance in *previous bleeding population*. (d) Performance in *secondary prophylaxis population*. CT: computed tomography; EVNTs: esophageal varices needing treatment; GVNTs: gastric varices needing treatment.](GRP2019-6704673.002){#fig2}

![Pitfalls in diagnosis of GEVs on contrast-enhanced CT. (a) Esophageal wall became stiff after repeated endoscopic treatments. (b) Small EVs were observed on contrast-enhanced CT, but missed on endoscopy. (c) GVs could not be evaluated as gastric cavity was not fully expanded. (d) GVs appeared as irregular vascular shadows, where the maximum diameter of varices was hard to be measured. CT: computed tomography; GEVs: gastroesophageal varices; EVs: esophageal varices; GVs: gastric varices.](GRP2019-6704673.003){#fig3}

![Line chart showing the relation between the rates of spared endoscopy and prevalence of EVNTs in different populations. EVNTs: esophageal varices needing treatment.](GRP2019-6704673.004){#fig4}

###### 

Baseline characteristics of patients.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                                                                   Primary prophylaxis population   Acute bleeding population   Previous bleeding population   Secondary prophylaxis population                                              
  --------------------------------------------------------------------------- -------------------------------- --------------------------- ------------------------------ ---------------------------------- ------- ------------------------- -------- -------------------------
  Age (years)                                                                 70                               56.67 ± 9.77\               38                             53.32 ± 12.52\                     67      53.11 ± 10.01\            104      57.10 ± 11.37\
                                                                                                               57.61 (26.74-78.64)                                        52.72 (20.58-80.79)                        50.56 (33.30-78.94)                58.31 (20.87-79.07)

  Sex (male)                                                                  70                               51 (72.9%)                  38                             32 (84.2%)                         67      50 (74.6%)                104      77 (74.0%)

  Etiology of liver diseases                                                                                                                                                                                                                            

   HBV infection                                                              70                               28 (40.0%)                  38                             13 (34.2%)                         67      23 (34.3%)                104      46 (44.2%)

   HCV infection                                                              70                               4 (5.7%)                    38                             2 (5.3%)                           67      9 (13.4%)                 104      9 (8.7%)

   Alcohol abuse                                                              70                               30 (42.9%)                  38                             17 (44.7%)                         67      29 (43.3%)                104      37 (35.6%)

   Drug related                                                               70                               8 (11.4%)                   38                             3 (7.9%)                           67      8 (11.9%)                 104      7 (6.7%)

   Autoimmune related                                                         70                               3 (4.3%)                    38                             1 (2.6%)                           67      3 (4.5%)                  104      7 (6.7%)

  Ascites                                                                     70                                                           38                                                                67                                104      

   No                                                                                                          33 (47.1%)                                                 14 (36.8%)                                 32 (47.8%)                         42 (40.4%)

   Mild                                                                                                        11 (15.7%)                                                 14 (36.8%)                                 18 (26.9%)                         40 (38.5%)

   Moderate-severe                                                                                             26 (37.1%)                                                 10 (26.3%)                                 17 (25.4%)                         22 (21.2%)

  Interval between prior endoscopic treatment and present admission (years)                                                                                                                                                                    100^a^   0.93 ± 0.99\
                                                                                                                                                                                                                                                        0.61 (0.10-5.78)

  Interval between CT and endoscopy (days)                                    70                               4.96 ± 3.85\                38                             2.50 ± 2.05\                       67      3.11 ± 2.46\              104      2.56 ± 2.45\
                                                                                                               4.00 (0.00-18.00)                                          2.00 (1.00-9.00)                           3.00 (0.00-17.00)                  2.00 (0.00-15.00)

   RBC (10^12^/L)                                                             70                               3.78 ± 0.68\                38                             2.73 ± 0.80\                       67      3.17 ± 0.82\              104      4.00 ± 0.63\
                                                                                                               3.88 (1.45-5.06)                                           2.58 (1.51-5.08)                           3.22 (1.15-5.05)                   4.05 (1.82-5.49)

   Hb (g/L)                                                                   70                               121.26 ± 22.19\             38                             80.16 ± 26.07\                     67      85.97 ± 25.91\            104      108.78 ± 22.36\
                                                                                                               124.00 (55.00-159.00)                                      75.50 (37.00-156.00)                       86.00 (28.00-154.00)               110.50 (33.00-161.00)

   WBC (10^9^/L)                                                              70                               4.83 ± 2.77\                38                             5.15 ± 4.15\                       67      3.76 ± 2.86\              104      3.70 ± 2.16\
                                                                                                               4.00 (1.80-20.80)                                          4.25 (1.10-22.40)                          3.20 (0.80-20.30)                  3.40 (0.80-16.70)

   PLT (10^9^/L)                                                              70                               103.57 ± 74.90\             38                             82.39 ± 39.11\                     67      95.71 ± 68.05\            104      111.91 ± 77.51\
                                                                                                               80.00 (22.00-423.00)                                       78.00 (26.00-162.00)                       76.00 (23.00-316.00)               89.50 (23.00-448.00)

   TBIL (*μ*mol/L)                                                            70                               47.34 ± 42.16\              38                             26.93 ± 20.95\                     67      27.11 ± 29.23\            104      21.59 ± 13.10\
                                                                                                               31.05 (6.60-216.50)                                        21.90 (5.20-119.30)                        20.00 (5.50-215.30)                18.30 (5.90-92.60)

   DBIL (*μ*mol/L)                                                            70                               25.23 ± 27.11\              38                             13.86 ± 14.12\                     67      14.60 ± 23.84\            104      8.94 ± 5.88\
                                                                                                               14.30 (2.00-149.90)                                        10.15 (2.00-81.80)                         8.90 (2.30-179.30)                 7.65 (2.10-48.90)

   ALB (g/L)                                                                  69                               32.44 ± 7.13\               38                             29.85 ± 5.92\                      67      32.95 ± 6.47\             103      35.71 ± 4.76\
                                                                                                               30.30 (19.20-50.60)                                        30.10 (19.00-45.40)                        33.60 (14.20-45.30)                35.90 (22.90-45.60)

   ALT (U/L)                                                                  70                               60.66 ± 73.48\              38                             40.08 ± 33.96\                     67      28.25 ± 18.58\            104      24.75 ± 12.09\
                                                                                                               36.72 (7.53-429.98)                                        26.21 (9.59-152.11)                        23.09 (4.47-99.13)                 21.07 (9.62-86.13)

   AST (U/L)                                                                  70                               75.95 ± 71.95\              38                             54.38 ± 42.90\                     67      41.76 ± 27.65\            104      33.03 ± 12.55\
                                                                                                               60.65 (13.94-394.45)                                       39.16 (10.99-202.40)                       32.88 (13.83-151.35)               30.30 (16.26-70.37)

   AKP (U/L)                                                                  70                               139.04 ± 76.06\             38                             99.51 ± 49.88\                     67      112.09 ± 65.98\           104      112.54 ± 62.90\
                                                                                                               113.19 (33.00-400.01)                                      84.54 (31.00-232.70)                       86.27 (40.65-399.34)               97.65 (30.04-466.34)

   GGT (U/L)                                                                  70                               171.27 ± 303.69\            38                             138.88 ± 241.13\                   67      74.81 ± 87.66\            104      64.32 ± 166.61\
                                                                                                               73.83 (10.93-1779.18)                                      49.57 (12.00-1227.00)                      34.10 (8.23-392.55)                32.50 (10.50-1680-03)

   BUN (mmol/L)                                                               70                               10.01 ± 40.54\              38                             8.14 ± 7.71\                       67      5.09 ± 1.76\              103      5.37 ± 1.95\
                                                                                                               4.98 (0.64-344.00)                                         5.72 (1.86-47.25)                          4.79 (1.57-9.38)                   5.12 (2.28-17.82)

   SCr (*μ*mol/L)                                                             70                               66.45 ± 20.42\              38                             75.14 ± 36.11\                     67      63.39 ± 15.67\            103      65.42 ± 16.68\
                                                                                                               64.65 (23.83-121.45)                                       72.62 (32.65-267.63)                       59.04 (37.66-114.13)               62.97 (36.39-141.50)

   PT (seconds)                                                               68                               16.27 ± 2.95\               38                             16.76 ± 3.59\                      67      16.48 ± 2.63\             102      15.64 ± 2.19\
                                                                                                               15.40 (11.20-28.00)                                        15.95 (11.60-27.20)                        16.40 (10.40-25.70)                15.20 (11.00-25.20)

   APTT (seconds)                                                             68                               41.64 ± 6.70\               38                             40.03 ± 4.71\                      67      40.72 ± 5.51\             102      40.37 ± 5.23\
                                                                                                               40.75 (28.00-64.80)                                        39.60 (30.80-51.00)                        40.10 (26.70-52.80)                39.80 (28.10-60.50)

   INR                                                                        68                               1.32 ± 0.31\                38                             1.40 ± 0.37\                       67      1.35 ± 0.26\              102      1.26 ± 0.22\
                                                                                                               1.25 (0.95-2.77)                                           1.31 (1.01-2.51)                           1.33 (0.90-2.39)                   1.22 (0.96-2.41)

  Child-Pugh class                                                            67^b^                                                        38                                                                67                                102^b^   

   A                                                                                                           20 (29.9%)                                                 11 (28.9%)                                 38 (56.7%)                         54 (52.9%)

   B                                                                                                           32 (47.8%)                                                 21 (55.3%)                                 23 (34.3%)                         47 (46.1%)

   C                                                                                                           15 (22.4%)                                                 6 (15.8%)                                  6 (9.0%)                           1 (1.0%)

  Child-Pugh score                                                            67^b^                            7.79 ± 2.16\                38                             7.68 ± 1.82\                       67      6.90 ± 1.78\              102^b^   6.50 ± 1.30\
                                                                                                               8.00 (5.00-13.00)                                          8.00 (5.00-12.00)                          6.00 (5.00-12.00)                  6.00 (5.00-10.00)

  MELD score                                                                  68^c^                            8.60 ± 6.06\                38                             8.28 ± 4.69\                       67      6.66 ± 4.59\              102^c^   5.80 ± 3.79\
                                                                                                               7.49 (-3.03-27.42)                                         7.83 (-3.16-16.73)                         6.35 (-2.73-24.73)                 5.30 (-1.75-19.12)

  Spleen diameter (mm)                                                        68^d^                            128.83 ± 27.63\             37^d^                          135.96 ± 27.30\                    60^d^   142.05 ± 25.59\           81^d^    147.97 ± 33.13\
                                                                                                               126.10 (59.80-190.30)                                      134.10 (66.60-189.70)                      143.55 (79.10-189.00)              147.40 (80.40-248.00)

  PSR                                                                         68^d^                            894.15 ± 786.97\            37^d^                          641.10 ± 380.74\                   60^d^   629.77 ± 483.09\          81^d^    626.04 ± 451.47\
                                                                                                               592.19 (177.99-3361.20)                                    567.40 (148.57-1654.75)                    458.57 (159.50-2703.67)            481.48 (121.95-2835.82)

  APRI score                                                                  70                               2.56 ± 2.29\                38                             1.99 ± 1.70\                       67      1.50 ± 1.20\              104      1.06 ± 0.67\
                                                                                                               1.87 (0.10-12.03)                                          1.74 (0.31-7.67)                           1.33 (0.12-6.10)                   0.90 (0.11-3.44)

  AAR score                                                                   70                               1.55 ± 0.79\                38                             1.49 ± 0.74\                       67      1.65 ± 0.84\              104      1.45 ± 0.46\
                                                                                                               1.43 (0.49-5.06)                                           1.31 (0.47-3.94)                           1.50 (0.44-5.41)                   1.38 (0.58-3.28)

  FIB-4 score                                                                 70                               7.73 ± 5.42\                38                             6.51 ± 4.02\                       67      6.08 ± 4.19\              104      5.13 ± 3.61\
                                                                                                               6.23 (0.71-22.42)                                          6.08 (0.96-20.33)                          5.57 (0.82-21.83)                  4.32 (0.72-17.58)

  King score                                                                  68^c^                            82.65 ± 90.75\              38                             61.56 ± 56.76\                     67      44.50 ± 39.43\            102^c^   31.63 ± 24.04\
                                                                                                               56.88 (2.02-495.85)                                        39.02 (7.26-219.22)                        31.94 (2.99-217.93)                24.46 (2.60-126.09)

  Lok score                                                                   68^c^                            0.80 ± 0.22\                38                             0.87 ± 0.14\                       67      0.86 ± 0.18\              102^c^   0.78 ± 0.22\
                                                                                                               0.89 (0.23-1.00)                                           0.92 (0.39-1.00)                           0.93 (0.16-1.00)                   0.87 (0.13-1.00)

  EVs                                                                         70                                                           38                                                                67                                104      

   No                                                                                                          27 (38.6%)                                                 3 (7.9%)                                   6 (9.0%)                           10 (9.6%)

   Yes                                                                                                         43 (61.4%)                                                 35 (92.1%)                                 61 (91.0%)                         94 (90.4%)

   Unknown                                                                                                     0 (0.0%)                                                   0 (0.0%)                                   0 (0.0%)                           0 (0.0%)

  EVNTs                                                                       70                                                           38                                                                67                                104      

   No                                                                                                          41 (58.6%)                                                 11 (28.9%)                                 17 (25.4%)                         62 (59.6%)

   Yes                                                                                                         26 (37.1%)                                                 27 (71.1%)                                 49 (73.1%)                         42 (40.4%)

   Unknown                                                                                                     3 (4.3%)^e^                                                0 (0.0%)                                   1 (1.5%)^e^                        0 (0.0%)

  GVs                                                                         70                                                           38                                                                67                                104      

   No                                                                                                          51 (72.9%)                                                 19 (50.0%)                                 18 (26.9%)                         68 (65.4%)

   Yes                                                                                                         18 (25.7%)                                                 19 (50.0%)                                 49 (73.1%)                         36 (34.6%)

   Unknown                                                                                                     1 (1.4%)^e^                                                0 (0.0%)                                   0 (0.0%)                           0 (0.0%)

  GVNTs                                                                       70                                                           38                                                                67                                104      

   No                                                                                                          60 (85.7%)                                                 23 (60.5%)                                 31 (46.3%)                         88 (84.6%)

   Yes                                                                                                         8 (11.4%)                                                  15 (39.5%)                                 36 (53.7%)                         16 (15.4%)

   Unknown                                                                                                     2 (2.9%)^e^                                                0 (0.0%)                                   0 (0.0%)                           0 (0.0%)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^The specific date of previous endoscopic treatment could not be obtained in 4 patients. ^b^Child-Pugh score could not be evaluated due to the absence of ALB or INR. ^c^MELD, King, and Lok score could not be evaluated due to the absence of INR. ^d^Spleen diameter and PSR were not available in patients with splenectomy. ^e^EVNTs, GVs, and GVNTs could not be evaluated due to the absence of detailed endoscopic reports. SD: standard deviation; HBV: hepatitis B virus; HCV: hepatitis C virus; CT: computed tomography; RBC: red blood cell; Hb: hemoglobin; WBC: white blood cell; PLT: platelet; TBIL: total bilirubin; DBIL: direct bilirubin; ALB: albumin; ALT: alanine aminotransferase; AST: aspartate aminotransferase; AKP: alkaline phosphatase; GGT-*γ*: glutamyl transpeptidase; BUN: blood urea nitrogen; SCr: serum creatinine; PT: prothrombin time; APTT: activated partial thromboplastin time; INR: international normalized ratio; MELD: model for end-stage liver disease; PSR: PLT count to spleen diameter ratio; APRI: AST to PLT ratio index; AAR: AST to ALT ratio; FIB4: fibrosis 4 index; EVs: esophageal varices; EVNTs: esophageal varices needing treatment; GVs: gastric varices; GVNTs: gastric varices needing treatment.

###### 

Diagnostic performance of alternative approaches.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables               Primary prophylaxis population   Acute bleeding population   Previous bleeding population   Secondary prophylaxis population                                                                                            
  ----------------------- -------------------------------- --------------------------- ------------------------------ ---------------------------------- --------------- -------------- ---- --------------- -------------- ----- --------------- ------------
  EVs                                                                                                                                                                                                                                             

   APRI score             70                               0.550\                      0.5207                         38                                 0.876\          **\<0.0001**   67   0.523\          0.8813         104   0.532\          0.7526
                                                           (0.426-0.669)                                                                                 (0.729-0.960)                       (0.398-0.647)                        (0.432-0.630)   

   AAR score              70                               0.550\                      0.5142                         38                                 0.714\          0.4083         67   0.672\          0.2117         104   0.513\          0.8961
                                                           (0.426-0.669)                                                                                 (0.545-0.849)                       (0.547-0.782)                        (0.413-0.613)   

   FIB4 score             70                               0.632\                      0.0852                         38                                 0.771\          **0.0314**     67   0.538\          0.8163         104   0.536\          0.7489
                                                           (0.508-0.744)                                                                                 (0.607-0.892)                       (0.412-0.661)                        (0.436-0.635)   

   King score             68                               0.586\                      0.2556                         38                                 0.838\          **0.0002**     67   0.500\          1.0000         102   0.525\          0.8078
                                                           (0.460-0.704)                                                                                 (0.683-0.937)                       (0.375-0.625)                        (0.424-0.625)   

   Lok score              68                               0.654\                      **0.0342**                     38                                 0.905\          **\<0.0001**   67   0.503\          0.9863         102   0.593\          0.4019
                                                           (0.529-0.766)                                                                                 (0.765-0.976)                       (0.378-0.627)                        (0.491-0.689)   

   PSR^∗^                 68                               0.755\                      **0.0001**                     37                                 0.882\          **\<0.0001**   60   0.664\          0.2587         81    0.633\          0.2900
                                                           (0.636-0.852)                                                                                 (0.734-0.965)                       (0.530-0.780)                        (0.519-0.738)   

   Contrast-enhanced CT   70                               0.680\                      **0.0004**                     38                                 0.833\          **0.0455**     67   0.833\          **0.0016**     104   0.739\          **0.0042**
                                                           (0.588-0.787)                                                                                 (0.677-0.934)                       (0.722-0.913)                        (0.644-0.821)   

  EVNTs                                                                                                                                                                                                                                           

   APRI score             67                               0.490\                      0.8912                         38                                 0.513\          0.8984         66   0.551\          0.5592         104   0.564\          0.2649
                                                           (0.366-0.615)                                                                                 (0.346-0.679)                       (0.424-0.674)                        (0.463-0.661)   

   AAR score              67                               0.475\                      0.7264                         38                                 0.648\          0.1905         66   0.547\          0.5854         104   0.616\          **0.0344**
                                                           (0.352-0.601)                                                                                 (0.477-0.796)                       (0.419-0.670)                        (0.516-0.710)   

   FIB4 score             67                               0.542\                      0.5567                         38                                 0.549\          0.6382         66   0.500\          1.0000         104   0.502\          0.9786
                                                           (0.416-0.665)                                                                                 (0.379-0.710)                       (0.374-0.626)                        (0.402-0.601)   

   King score             65                               0.516\                      0.8272                         38                                 0.505\          0.9608         66   0.571\          0.4147         102   0.519\          0.7456
                                                           (0.389-0.642)                                                                                 (0.338-0.671)                       (0.444-0.693)                        (0.418-0.619)   

   Lok score              65                               0.557\                      0.4315                         38                                 0.582\          0.4786         66   0.570\          0.4231         102   0.546\          0.4251
                                                           (0.428-0.680)                                                                                 (0.412-0.740)                       (0.442-0.691)                        (0.444-0.644)   

   PSR^∗^                 65                               0.670\                      **0.0126**                     37                                 0.738\          **0.0127**     59   0.688\          **0.0185**     81    0.595\          0.1428
                                                           (0.542-0.782)                                                                                 (0.567-0.868)                       (0.554-0.802)                        (0.480-0.703)   

   Contrast-enhanced CT   67                               0.876\                      **\<0.0001**                   38                                 0.816\          **0.0001**     66   0.873\          **\<0.0001**   103   0.673\          **0.0012**
                                                           (0.772-0.944)                                                                                 (0.658-0.923)                       (0.768-0.942)                        (0.574-0.762)   

  GVs                                                                                                                                                                                                                                             

   APRI score             69                               0.541\                      0.5846                         38                                 0.589\          0.3527         67   0.588\          0.2517         104   0.532\          0.6022
                                                           (0.417-0.662)                                                                                 (0.418-0.745)                       (0.461-0.707)                        (0.432-0.631)   

   AAR score              69                               0.709\                      **0.0009**                     38                                 0.611\          0.2412         67   0.549\          0.5593         104   0.565\          0.2948
                                                           (0.587-0.812)                                                                                 (0.439-0.764)                       (0.423-0.671)                        (0.464-0.662)   

   FIB4 score             69                               0.636\                      0.0679                         38                                 0.535\          0.7206         67   0.621\          0.1027         104   0.499\          0.9867
                                                           (0.512-0.749)                                                                                 (0.366-0.698)                       (0.494-0.737)                        (0.399-0.599)   

   King score             67                               0.546\                      0.5393                         38                                 0.554\          0.5756         67   0.618\          0.1236         104   0.508\          0.8952
                                                           (0.420-0.669)                                                                                 (0.384-0.715)                       (0.491-0.734)                        (0.407-0.609)   

   Lok score              67                               0.672\                      **0.0079**                     38                                 0.551\          0.6018         67   0.499\          0.9944         102   0.534\          0.5642
                                                           (0.547-0.782)                                                                                 (0.382-0.713)                       (0.375-0.624)                        (0.432-0.633)   

   PSR^∗^                 67                               0.664\                      **0.0236**                     37                                 0.614\          0.2334         60   0.603\          0.2093         81    0.510\          0.8834
                                                           (0.538-0.774)                                                                                 (0.440-0.769)                       (0.469-0.727)                        (0.396-0.623)   

   Contrast-enhanced CT   68                               0.721\                      **0.0005**                     38                                 0.605\          0.1797         67   0.671\          **0.0076**     102   0.686\          **0.0001**
                                                           (0.599-0.823)                                                                                 (0.434-0.760)                       (0.546-0.781)                        (0.586-0.774)   

  GVNTs                                                                                                                                                                                                                                           

   APRI score             68                               0.583\                      0.4108                         38                                 0.559\          0.5561         67   0.575\          0.3073         104   0.612\          0.1463
                                                           (0.457-0.702)                                                                                 (0.389-0.720)                       (0.448-0.695)                        (0.511-0.706)   

   AAR score              68                               0.648\                      0.0691                         38                                 0.601\          0.2862         67   0.637\          **0.0499**     104   0.536\          0.6585
                                                           (0.523-0.760)                                                                                 (0.430-0.756)                       (0.510-0.751)                        (0.436-0.635)   

   FIB4 score             68                               0.598\                      0.3457                         38                                 0.478\          0.8230         67   0.614\          0.1072         104   0.646\          **0.0480**
                                                           (0.472-0.715)                                                                                 (0.314-0.646)                       (0.487-0.731)                        (0.546-0.738)   

   King score             66                               0.558\                      0.5559                         38                                 0.513\          0.8954         67   0.616\          0.1092         102   0.627\          0.1144
                                                           (0.431-0.680)                                                                                 (0.346-0.678)                       (0.489-0.732)                        (0.525-0.721)   

   Lok score              66                               0.626\                      0.1504                         38                                 0.536\          0.7158         67   0.497\          0.9661         102   0.524\          0.7894
                                                           (0.498-0.742)                                                                                 (0.367-0.699)                       (0.372-0.622)                        (0.422-0.624)   

   PSR^∗^                 67                               0.631\                      0.2201                         37                                 0.615\          0.2333         60   0.555\          0.4711         81    0.579\          0.4057
                                                           (0.505-0.746)                                                                                 (0.441-0.770)                       (0.421-0.684)                        (0.464-0.687)   

   Contrast-enhanced CT   64                               0.731\                      **0.0316**                     35                                 0.639\          0.1502         64   0.602\          0.1628         100   0.661\          **0.0259**
                                                           (0.605-0.834)                                                                                 (0.460-0.794)                       (0.472-0.723)                        (0.559-0.753)   
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^∗^PSR was not available in patients with splenectomy. APRI: aspartate aminotransferase to platelet ratio index; AAR: aspartate aminotransferase to alanine aminotransferase ratio; FIB4: fibrosis 4 index; PSR: platelet count to spleen diameter ratio; CT: computed tomography; AUC: area under the curve; CI: confidence interval; EVs: esophageal varices; EVNTs: esophageal varices needing treatment; GVs: gastric varices; GVNTs: gastric varices needing treatment.

[^1]: Academic Editor: Mario Pirisi
